Avalo Therapeutics (NASDAQ:AVTX) focuses on discovering and developing innovative treatments for patients suffering from complex autoimmune and rare diseases. The company’s operations are mainly concentrated on advancing its pipeline of unique drug candidates through various stages of clinical trials, with the aim to provide new, effective options for conditions with high unmet medical needs. Avalo's projects span a wide range of disorders, including but not limited to, immunology and rare diseases, where the goal is to significantly improve patients' quality of life. Avalo is dedicated to achieving breakthroughs in treatment through rigorous research, clinical development, and strategic collaborations.